UK markets closed

ZYME Oct 2024 7.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.30000.0000 (0.00%)
At close: 02:15PM EDT
Full screen
Previous close3.3000
Open3.3000
Bid3.2000
Ask4.5000
Strike7.50
Expiry date2024-10-18
Day's range3.3000 - 3.3000
Contract rangeN/A
Volume2
Open interest21
  • GlobeNewswire

    Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

    VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. “After an extensive search, we are delighted to have Leone Patterson join us at

  • GlobeNewswire

    Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

    VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW191, the Company’s novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i

  • GlobeNewswire

    Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

    VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial result